Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
NCT06257394Phase 2Recruiting
- Start
- Oct 2024
- Primary completion
- Dec 2034
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, scFv Fragments
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in acute lymphoblastic leukemia (ALL). Started Oct 2024; status: recruiting.
02
Drugs
dasatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06257394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06257394.